Adalimumab is the most commonly prescribed biological and is approved for rheumatoid arthritis as well as psoriasis psoriatic arthritis along with Crohns and ulcerative colitis. Its patent life terminated in 2016 in the US 1. However in the US AbbVie has s...
↧